The biotechnology industry is constantly evolving, and one of the latest innovations to emerge from France is Vect-Horus. Based in Marseille, this company specializes in creating molecular vectors that enable targeted delivery of therapeutic molecules and imaging agents.
Vect-Horus has announced its participation at the Viva Technology conference in Paris from May 22-25, 2024. As one of ten startups chosen by France’s National Center for Scientific Research (CNRS) to showcase their innovative technologies, Vect-Horus will present its VECTrans® technology, a unique breakthrough in drug targeting for the brain and other pathological tissues such as cancers.
Jean-Manuel Pean, the Chief Scientific Officer of Vect-Horus, will be part of a roundtable discussion where he will provide an overview of the company and its pipeline. He will discuss progress made with VECTrans® technology, early clinical trials of their theragnostic agent for glioblastoma and pancreatic cancer, and update on partnerships including agreements with Novo Nordisk and Ionis Pharmaceuticals.
The detailed roundtable program will be announced closer to the event. Founded in 2005 as a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), Vect-Horus focuses on developing vectors for targeting and delivering therapeutic or imaging agents to organs and tumors. With 38 employees predominantly in research and development, this biotechnology company continues to make strides in its field. For more information about Vect-Horus, visit their website at www.vect-horus.com. For media inquiries or press releases, contact them at contact@vect-horus.com. For any other information reach out to their Business Development and Alliance Manager Emmanuelle Bettendorf or Cohesion Bureau’s media relations team